Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Discovery Research In Japan By Global Pharmas: Evolving More Toward Partnerships? (Part 1 of 3)

This article was originally published in The Pink Sheet Daily

Executive Summary

While some globe-spanning pharmaceutical companies are maintaining or increasing their investment in discovery research in Japan, many more are moving in the opposite direction.

You may also be interested in...



Banyu to Close Tsukuba Lab as Part of Merck’s Global Research Revamp

TOKYO - Merck subsidiary Banyu Pharmaceutical, said Oct. 23 it would close its research laboratory in Tsukuba City, northeast of Tokyo, by the end of 2009, leaving only a fraction of foreign drug makers with basic research activities in Japan

Pfizer Head of R&D Business Development – Asia Alex Fowkes On Matching Global Partners With Pfizer’s Pipeline: An Interview With PharmAsia News (Part 2 of 2)

Pfizer's Head of R&D Business Development - Asia Alex Fowkes sat down with PharmAsia News' Australia bureau to discuss Pfizer's business development and research strategies in Asia. Fowkes recently addressed a panel at the BioAsia conference in Singapore and discussed Pfizer's virtual approach to doing business in Asia, which offers more flexibility and creative approaches (PharmAsia News, May 8, 2008).

Pfizer Avoids Japan R&D Layoffs With Creation Of New Business

Pfizer is spinning off some of its Nagoya, Japan, research site into a venture-backed start-up called RaQualia Pharma Inc., the company reported July 3

Related Content

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel